Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.
Aragon-Ching
Jeanny B
JB
Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA. chingj@mail.nih.gov
Ning
Yang-Min
YM
Chen
Clara C
CC
Latham
Lea
L
Guadagnini
Jean-Pierre
JP
Gulley
James L
JL
Arlen
Philip M
PM
Wright
John J
JJ
Parnes
Howard
H
Figg
William D
WD
Dahut
William L
WL
D000328:Adult; D000368:Aged; D019386:Alendronate / Q000009:adverse effects; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D000077557:Ibandronic Acid; D015994:Incidence; D007571:Jaw Diseases / Q000139:chemically induced / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010020:Osteonecrosis / Q000139:chemically induced / Q000453:epidemiology*; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D020533:Angiogenesis Inhibitors; D004164:Diphosphonates; D000077557:Ibandronic Acid; D019386:Alendronate